NeoPharm CO., LTD. (KOSDAQ:092730)

Market Cap	346.45B +61.3%
Revenue (ttm)	132.18B +11.1%
Net Income	27.82B +20.6%
EPS	1,778.81 +20.6%
Shares Out	15.64M
PE Ratio	12.45
Forward PE	10.82
Dividend	750.00 (3.54%)
Ex-Dividend Date	Dec 29, 2025

Volume	76,138
Average Volume	75,787
Open	22,000
Previous Close	22,150
Day's Range	20,000 - 22,000
52-Week Range	13,020 - 22,650
Beta	0.57
RSI	60.73
Earnings Date	May 8, 2026

About NeoPharm CO., LTD.

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2000
• Employees: 178
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2025, NeoPharm CO., LTD.'s revenue was 132.18 billion, an increase of 11.07% compared to the previous year's 119.01 billion. Earnings were 27.82 billion, an increase of 20.63%.